Structure Therapeutics Management
Management criteria checks 1/4
Structure Therapeutics' CEO is Raymond Stevens, appointed in May 2019, has a tenure of 5.5 years. total yearly compensation is $7.39M, comprised of 8.1% salary and 91.9% bonuses, including company stock and options. directly owns 1.32% of the company’s shares, worth $25.15M. The average tenure of the management team and the board of directors is 2.9 years and 1.9 years respectively.
Key information
Raymond Stevens
Chief executive officer
US$7.4m
Total compensation
| CEO salary percentage | 8.1% |
| CEO tenure | 5.5yrs |
| CEO ownership | 1.3% |
| Management average tenure | 2.9yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Nov 25
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Oct 22We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely
Aug 11Structure Therapeutics: Yet Another Potential GLP-1 Entrant
Jun 14Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape
Jun 05Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation
Mar 10Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans
Jun 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$111m |
| Jun 30 2024 | n/a | n/a | -US$100m |
| Mar 31 2024 | n/a | n/a | -US$98m |
| Dec 31 2023 | US$7m | US$596k | -US$90m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$66m |
| Mar 31 2023 | n/a | n/a | -US$58m |
| Dec 31 2022 | US$747k | US$487k | -US$53m |
| Sep 30 2022 | n/a | n/a | -US$56m |
| Dec 31 2021 | US$1m | US$420k | -US$44m |
Compensation vs Market: Raymond's total compensation ($USD7.39M) is above average for companies of similar size in the US market ($USD5.50M).
Compensation vs Earnings: Raymond's compensation has increased whilst the company is unprofitable.
CEO
Raymond Stevens (60 yo)
5.5yrs
Tenure
US$7,390,911
Compensation
Dr. Raymond C. Stevens, Ph.D. is Professor of Molecular Biology and Chemistry at The Scripps Research Institute, La Jolla, California since 1999 until July 2014. He has been the Chief Executive Officer at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.5yrs | US$7.39m | 1.32% $ 25.2m | |
| Co- Founder | 2.5yrs | US$3.67m | 1.53% $ 29.2m | |
| Chief Technology Officer | 2.3yrs | US$1.24m | 0% $ 0 | |
| Chief Scientific Officer | 5.3yrs | no data | no data | |
| Senior Vice President of Legal | no data | no data | no data | |
| Senior Vice President of People | less than a year | no data | no data | |
| Senior Vice President of Chemistry | 2.8yrs | no data | no data | |
| Executive VP & Head of Biology | no data | no data | no data | |
| Senior Vice President of Clinical Development Operations | no data | no data | no data | |
| Senior Vice President of Preclinical Development | no data | no data | no data | |
| Senior Vice President of Cardiopulmonary Clinical Development | 3.8yrs | no data | no data | |
| Senior VP & Head of Biology Structure of ShouTi Basecamp Bio | 2.9yrs | no data | no data |
2.9yrs
Average Tenure
50yo
Average Age
Experienced Management: GPCR's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$7.39m | 1.32% $ 25.2m | |
| Independent Director | 2.7yrs | US$64.00k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Independent Chairman | 2.8yrs | US$242.63k | 0.072% $ 1.4m | |
| Independent Director | 1.3yrs | US$655.05k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$57.50k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$49.00k | 0% $ 0 |
1.9yrs
Average Tenure
64yo
Average Age
Experienced Board: GPCR's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.